Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
复制标题
DOI：
10.1177/1533033820950832
复制
发表时间：
2020-01
影响因子：
2.8
通讯作者：
Wang LX
中科院分区：
文献类型：
--
作者：
Lian J;Xu EW;Xi YF;Wang HW;Bu P;Wang JF;Wang LX
最近显示PIK3CA突变在乳腺肿瘤的发病机制和进展中发挥重要作用。中国乳腺癌患者中 PIK3CA 的患病率可能被低估。因此，我们研究了中国乳腺癌患者体细胞PIK3CA突变的分布，并探讨其在肿瘤表型中的作用。采用扩增难治性突变系统（ARMS）对113例中国女性原发性乳腺癌进行PIK3CA突变分析。分析了 PIK3CA 突变与多种临床病理特征的关系。 PIK3CA基因突变43例（38.05%），外显子9和20之间差异更显着。43例PIK3CA突变者HER2基因扩增率为32.6%，70例非突变者HER2基因扩增率为37.1%（χ2 = 0.245，P > 0.05）。两组年龄分布、淋巴结状况、肿瘤组织学分级、ER和/或PR、P53差异无统计学意义（P > 0.05）。中国乳腺癌患者中检测到高频率的体细胞PIK3CA突变，尤其是20号外显子。PIK3CA基因突变与乳腺癌临床病理特征的关系需要在大量患者中进一步研究。 PIK3CA 突变似乎有潜力用于靶向治疗并作为预后指标。
Mutations of PIK3CA have recently been shown to play an important role in the pathogenesis and progression of breast neoplasms. The prevalence of PIK3CA in Chinese breast cancer patients may be underestimated. Therefore, we investigated the distribution of somatic PIK3CA mutation in Chinese breast cancer patients and explored their role in tumor phenotypes. Mutational analysis of PIK3CA was done in 113 primary breast cancers of Chinese women used Amplification refractory mutation system (ARMS). The relationship of PIK3CA mutations with several clinicopathologic characteristics was analyzed. PIK3CA gene mutation was identified in 43(38.05%) cases and has a more significant difference between exon 9 and 20. HER2 gene amplification was 32.6% in 43 cases of PIK3CA mutation, but 37.1% in 70 cases of non-mutation (χ2 = 0.245, P > 0.05). There was no significant correlation of the age distribution, lymph node status, histological tumor grading, ER and/or PR and P53 between 2 groups (P > 0.05). A high frequency of somatic PIK3CA mutation was detected in Chinese breast cancer patients, especially in exon 20. The relationship between PIK3CA gene mutation and clinical pathological features of breast cancer needs to be further studied in a large series of patients. PIK3CA mutations seem to have the potential to be used in target treatment and as an indicator of prognosis.
登录
查看更多内容
影响因子：
4.6
作者：
Deng L;Zhu X;Sun Y;Wang J;Zhong X;Li J;Hu M;Zheng H
通讯作者：
Zheng H
DOI：
10.1080/07391102.2016.1231082
发表时间：
2017-01-01
影响因子：
4.4
作者：
Kumar, D. Thirumal;Doss, C. George Priya
通讯作者：
Doss, C. George Priya
乳腺上皮细胞中同时发生的 HER2 和突变 PIK3CA 的协同致癌效应和细胞信号传导串扰。
影响因子：
5.2
作者：
Dong L;Meng F;Wu L;Mitchell AV;Block CJ;Zhang B;Craig DB;Jang H;Chen W;Yang Q;Wu G
通讯作者：
Wu G
影响因子：
7.3
作者：
Buttitta, F;Felicioni, L;Marchetti, A
通讯作者：
Marchetti, A
影响因子：
11.2
作者：
Stemke-Hale K;Gonzalez-Angulo AM;Lluch A;Neve RM;Kuo WL;Davies M;Carey M;Hu Z;Guan Y;Sahin A;Symmans WF;Pusztai L;Nolden LK;Horlings H;Berns K;Hung MC;van de Vijver MJ;Valero V;Gray JW;Bernards R;Mills GB;Hennessy BT
通讯作者：
Hennessy BT